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OBJECTIVES This study characterized clinical factors predictive of cardiogenic shock developing after
thrombolytic therapy for acute myocardial infarction (AMI).
BACKGROUND Cardiogenic shock remains a common and ominous complication of AMI. By identifying
patients at risk of developing shock, preventive measures may be implemented to avert its
development.
METHODS We analyzed baseline variables associated with the development of shock after thrombolytic
therapy in the Global Utilization of Streptikonase and Tissue-Plasminogen Activator for
Occluded Coronary Arteries (GUSTO-I) trial. Using a Cox proportional hazards model, we
devised a scoring system predicting the risk of shock. This model was then validated in the
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) cohort.
RESULTS Shock developed in 1,889 patients a median of 11.6 h after enrollment. The major factors
associated with increased adjusted risk of shock were age (x2 5 285, hazard ratio [95%
confidence interval] 1.47 [1.40, 1.53]), systolic blood pressure (x2 5 280), heart rate (x2 5
225) and Killip class (x2 5 161, hazard ratio 1.70 [1.52, 1.90] and 2.95 [2.39, 3.63] for Killip
II versus I and Killip III versus I, respectively) upon presentation. Together, these four
variables accounted for .85% of the predictive information. These findings were transformed
into an algorithm with a validated concordance index of 0.758. Applied to the GUSTO-III
cohort, the four variables accounted for .95% of the predictive information, and the validated
concordance index was 0.796.
CONCLUSIONS A scoring system accurately predicts the risk of shock after thrombolytic therapy for AMI
based primarily on the patient’s age and physical examination on presentation. (J Am Coll
Cardiol 2000;35:136–43) © 1999 by the American College of Cardiology
Cardiogenic shock remains a relatively common complica-
tion of acute myocardial infarction (AMI), still portending
an ominous prognosis despite the advent of new or refined
therapeutic strategies (1–18). By identifying patients at risk
for developing cardiogenic shock, preventive measures may
be implemented in an attempt to avert the development of
shock. The aim of the current study was to develop a model
to predict the occurrence of cardiogenic shock among
patients with AMI receiving thrombolytic therapy in the
Global Utilization of Streptokinase and Tissue-
Plasminogen Activator for Occluded Coronary Arteries-I
(GUSTO-I) trial (19) and to validate it in another large
cohort of patients receiving thrombolytic therapy for AMI.
METHODS
The details and results of the GUSTO-I trial have been
previously reported (19). In brief, 41,021 patients from 15
countries presenting within 6 h of the onset of chest pain
with typical electrocardiographic (ECG) changes (.0.1 mV
ST-segment elevation in $2 limb leads or .0.2 mV in $2
precordial leads) were eligible for randomization to one of
four intravenous (IV) thrombolytic strategies: 1) streptoki-
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nase (Kabikinase, Kabi Vitrum, Stockholm, Sweden), 1.5
million U over 1 h, with subcutaneous heparin; 2) strep-
tokinase with IV heparin; 3) accelerated recombinant tissue-
type plasminogen activator (Activase, Genentech, South
San Francisco, California), 15 mg bolus followed by infu-
sion at 0.75 mg/kg (#50 mg) for 30 min and 0.5 mg/kg
(#35 mg) over the next hour, and IV heparin; 4) tissue-type
plasminogen activator (1.0 mg/kg over 1 h (#90 mg)) and
streptokinase (1 million U over 1 h) with IV heparin.
Adjunctive therapy included chewable aspirin ($160 mg;
Bayer) followed by 160 to 325 mg/day, and IV atenolol
(10 mg; ICI Pharmaceuticals, Wilmington, Delaware) fol-
lowed by daily oral therapy (50 to 100 mg).
Other medications were given at the discretion of the
attending physician. Angiography, right-heart catheteriza-
tion, percutaneous coronary revascularization, intraaortic
balloon pumping and coronary bypass surgery were also
used at the discretion of the attending physician.
Patients with cardiogenic shock were prospectively iden-
tified (5,15,16,18). Cardiogenic shock was defined as sys-
tolic blood pressure ,90 mm Hg for $1 h that was not
responsive to fluid administration alone, thought to be
secondary to cardiac dysfunction, and associated with signs
of hypoperfusion or cardiac index #2.2 liters/min/mm2 and
pulmonary capillary wedge pressure .18 mm Hg. Patients
in whom systolic blood pressure increased to .90 mm Hg
within 1 h after administration of positive inotropic agents,
or patients who died within 1 h of hypotension but met
other criteria for cardiogenic shock, were still classified as
having cardiogenic shock. In the current analysis we ex-
cluded patients who presented with shock or who were
missing precise data as to the timing of shock relative to the
time of enrollment. To characterize the temporal relation-
ship of shock to thrombolytic therapy, the occurrence of
shock was also analyzed based on its timing after enroll-
ment: #1 h, .1 to 2 h, .2 to 6 h, .6 to 24 h, .24 to 48 h,
and .48 h.
Statistical analysis. Continuous variables are presented as
medians with 25th and 75th percentiles and discrete vari-
ables as frequencies and percentages. Multivariable Cox
proportional hazards survival modeling techniques were
used to develop a model to predict the time to in-hospital
cardiogenic shock. Missing characteristics were imputed for
all patients with partial data using a method for simulta-
neous imputation and transformation of predictor variables
based on the concepts of maximum generalized variance and
canonical variables (20). A backward-elimination method
was used to determine the significant predictors in the
model (elimination criterion, p . 0.05). Because the precise
timing was not available for invasive procedures such as
angioplasty or intraaortic balloon counterpulsation, we did
not include these variables in our analyses. Predictors in the
above models were tested using the Wald chi-square test.
Results are also presented as hazard ratios and 95% confi-
dence intervals (CI). Once the final model was developed,
bootstrapping was used (21,22) for internal validation (100
bootstrapping samples). The quality of the final model
based on the original as well as the bootstrapped samples is
described with the use of the concordance index, which is a
description of the discriminant power of the model to
reliably predict an outcome (23).
On the basis of the coefficients in the model, a probability
chart was developed for the occurrence of shock in-hospital.
As we previously described (18), each variable in the model
received a certain score based on the value of the variable.
The total points were then transformed into predictive
values.
Validation. For verification purposes, the model we devel-
oped in the GUSTO-I cohort was used in the Global Use
of Strategies to Open Occluded Coronary Arteries III
(GUSTO-III) cohort (24). In GUSTO-III, 30-day out-
come of patients randomized to receive either reteplase or
alteplase was equivalent. We have previously reported that
treatment with alteplase versus reteplase did not have an
effect on the occurrence or the outcome of shock in
GUSTO-III (25).
Of the 15,058 patients enrolled in GUSTO-III, we
eliminated 83 from this analysis because they presented with
shock and an additional 15 because we were unable to
determine from available data when they developed shock;
this left a modeling sample of 14,960 patients. We tested
the GUSTO-I shock model in this GUSTO-III popula-
tion, of whom 643 patients developed cardiogenic shock
after enrollment.
RESULTS
Patient population. Of the 41,021 patients enrolled in the
GUSTO-I trial, data regarding shock status were missing
for 305. Of the remaining 40,716 patients, 680 were
excluded because they developed shock prior to enrollment,
and 383 were excluded because they had severe hemody-
namic compromise after enrollment but did not meet our
strict criteria for shock. This analysis pertains to the 1,889
patients who unequivocally developed shock after admis-
sion.
Time to shock. The median time from enrollment to
shock was 11.6 (2.2, 41.9) h. Shock developed within 6 h of
enrollment in 39.6% of shock patients and within 24 h in
Abbreviations and Acronyms
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CI 5 confidence interval
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GUSTO-I 5 Global Utilization of Streptokinase and
Tissue-Plasminogen Activator for
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Occluded Coronary Arteries
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63.2% (Table 1). The vast majority of shock patients
(97.7%) received thrombolytic therapy, although only 79.4%
received such treatment as stipulated by the protocol. The
median time from onset of symptoms to treatment was 3.0
(2.1, 4.1) h for the shock patients.
Baseline characteristics. In general, the patients who de-
veloped shock after enrollment were older than nonshock
patients and were more commonly women. The shock
patients also had more co-morbid conditions such as hyper-
tension and diabetes mellitus, but they were less frequently
cigarette smokers. More shock patients had experienced a
prior infarction. The physical examination revealed that
more shock patients arrived with Killip classes II and III and
that upon presentation their systemic blood pressure was
lower and their heart rate higher.
There were several differences in baseline characteristics
among the various shock groups categorized based on the
timing of shock (Table 1). Shock developed earlier in
younger patients who were more commonly cigarette smok-
ers and more frequently had inferior wall AMI. The patients
with early shock had lower blood pressure upon presentation
without a significant difference in heart rate or Killip class.
Model. In the Cox proportional hazards survival model
(Table 2), the major factors associated with increased
adjusted risk of shock were age (x2 5 285, hazard ratio and
95% CI of 1.47 [1.40, 1.53]), as well as systolic blood
pressure (x2 5 280), heart rate (x2 5 225) and Killip class
(x2 5 161, hazard ratio of 1.70 [1.52, 1.90] and 2.95 [2.39,
3.63] for Killip class II vs. class I and Killip class III vs. Class
I, respectively) upon presentation. Together, these four
variables provided .85% of the information needed to
predict the occurrence of shock.
The relationship between age, weight, and diastolic blood
pressure and developing shock was linear. The relationship
between the systolic blood pressure and heart rate and
developing shock was more complex, as is evident in Figures
1 and 2, respectively.
Algorithm. We converted the results of the model into a
scoring system algorithm (Table 3). Based on certain
categorical clinical features such as prior AMI or gender, as
well as the value of continuous variables such as age or
systolic blood pressure upon presentation, a composite score
can be calculated. This composite score can then be used to
estimate the risk of developing shock after thrombolytic
therapy.
Validation. The same four variables as in the GUSTO-I
model were significant in the GUSTO-III population: age
(x2 5 96, hazard ratio of 1.49 [1.38, 1.62]), systolic blood
pressure (x2 5 138), heart rate (x2 5 94) and Killip class
(x2 5 82; hazard ratio of 2.0 [1.65, 2.43] and hazard ratio
of 3.34 [2.43, 4.61] for Killip class II vs. class I and Killip
class III vs. class I, respectively). These four variables
accounted for .95% of the predictive information in the
GUSTO-III population. The validated concordance index
was 0.796.
DISCUSSION
Current therapeutic approaches to cardiogenic shock remain
of limited efficacy. Even using aggressive revascularization
interventions, short-term mortality has reached .70% in
recent series of shock patients (8,17). In the absence of
overwhelmingly effective treatments for shock, an alterna-
tive approach is to identify patients at high risk for devel-
oping shock and to attempt to avert its development. In the
present study we identified 1,889 patients who developed
cardiogenic shock after they were enrolled and who were
randomized to various thrombolytic therapies in the
GUSTO-I trial. Using this population, we developed a
model to predict the occurrence of shock. To validate it, we
applied it to the GUSTO-III patient population.
Predictors of shock. Our findings demonstrate that certain
demographic and clinical parameters are strongly associated
with the development of shock after thrombolytic therapy.
Older age was the variable most strongly associated with the
occurrence of shock: for every 10-year increase in age, the
Table 2. Baseline Independent Predictors of Developing
Cardiogenic Shock
Characteristic
Wald
x2 df
p-
Value
Hazard
Ratio 95% CI
Age 285.14 1 , 0.001 1.47* (1.40, 1.53)
Systolic BP 279.55 2 , 0.001
Heart rate 225.28 3 , 0.001
Killip class 161.35 2 , 0.001
II vs. I 1.70 (1.52, 1.90)
III vs. I 2.95 (2.39, 3.63)
MI location 77.05 2 , 0.001
Anterior vs. other 1.62 (1.21, 2.15)
Inferior vs. other 1.07 (0.80, 1.43)
U.S. 43.92 1 , 0.001 1.39 (1.26, 1.53)
Treatment 36.87 3 , 0.001
SK-IV vs. tPA 1.39 (1.22, 1.59)
Combo vs. tPA 1.22 (1.07, 1.40)
SK-SQ vs. tPA 1.46 (1.28, 1.66)
Previous MI 25.61 1 , 0.001 1.34 (1.20, 1.50)
Previous CABG 15.38 1 , 0.001 1.46 (1.21, 1.76)
Weight 13.65 1 , 0.001 0.94* (0.91, 0.97)
Female 12.69 1 , 0.001 1.22 (1.09, 1.35)
Hypertension 8.42 1 0.004 1.15 (1.05, 1.26)
Previous PTCA 7.31 1 0.007 0.70 (0.54, 0.91)
Diastolic BP 5.73 2 0.017 1.06* (1.01, 1.11)
*Hazard ratio is for an increase of 10 U. The hazard ratios are not presented for heart
rate and BP because the relationship was nonlinear.
Overall model x2 5 1,789 with 21 d.f., n 5 38,942 with 1,889 events Concordance
index 5 0.761, validated model 5 0.758. The variables included in the model are
listed in Table 1.
CI 5 confidence interval; BP 5 blood pressure; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty; CABG 5 coronary artery
bypass grafting surgery; tPA 5 tissue-plasminogen activator; SK 5 streptokinase;
IV 5 intravenous; Combo 5 combination of tissue-plasminogen activator and
streptokinase; SQ 5 subcutaneous.
139JACC Vol. 35, No. 1, 2000 Hasdai et al.
January 2000:136–43 Predictors of Shock After Thrombolysis for AMI
risk of developing shock was greater by 47%. In addition,
simple parameters derived from the physical examination,
such as systolic blood pressure, heart rate and Killip class
among patients who did not present with shock, were strong
predictors of shock developing subsequently. Together, the
patient’s age and these physical parameters provided .85% of
the information needed to predict shock in our model. These
variables have also been shown to be major predictors of 30-day
mortality in an analysis of the entire GUSTO-I cohort (26).
Comparison with prior studies. Leor et al. (27) previously
reported that in the prethrombolysis era, among patients
Figure 1. The relationship between systolic blood pressure (BP) upon presentation and the probability of shock developing after
thrombolytic therapy.
Figure 2. The relationship between heart rate upon presentation and the probability of shock developing after thrombolytic therapy.
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Table 3. Baseline Predictors of Cardiogenic Shock
1. Find points for each predictive factor
Age Heart Rate (HR) Systolic BP Diastolic BP
Yrs Points Beats/min Points mm Hg Points mm Hg Points
20 6 40 3 80 59 40 4
30 12 60 0 100 49 60 5
40 19 80 8 120 39 80 7
50 25 100 14 140 32 100 9
60 31 120 17 160 27 120 11
70 37 140 19 180 23 140 13
80 43 160 22 200 18 160 15
90 49 180 24 220 14 180 16
200 27 240 9 200 18
220 29 260 5
240 32 280 0
260 34
Weight Treatment Killip Class
kg Points Tx Points Class Points
40 19 TPA 0 I 0
60 17 SK-IV 5 II 9
80 15 Combo 3 III 17
100 12 SK-SQ 6
120 10
140 8 MI Location Miscellaneous Risk Factors
160 6 Previous MI 5
180 4 Ant. 8 Previous CABG 6
200 2 Inf. 1 No previous PTCA 6
220 0 Other 0 Female 3
Hypertension 2
US 5
2. Sum points for all predictive factors:
Age HR 1 Sys
BP
1 Dia
BP
1 Wgt 1 Tx 1 MI
loc
1 Killip
Class
Msc 5 Total
Pts
3. Look up risk corresponding to total points:
Points
Probability of In-hospital
Cardiogenic Shock
92 1%
103 2%
110 3%
114 4%
118 5%
130 10%
137 15%
142 20%
146 25%
149 30%
152 35%
155 40%
158 45%
160 50%
In panel 1, find the value most closely matching the patient’s risk factors and circle the points. In panel 2, sum the points for all predictive factors. In panel 3, determine the
predicted occurrence of cardiogenic shock corresponding to the total number of points. For example, a 71-year-old 60-kg female from the U.S. with a history of hypertension,
who presents with a systolic blood pressure of 126 mm Hg, a diastolic blood pressure of 64 mm Hg, a heart rate of 123 beats/min, in Killip class III, and an anterior myocardial
infarction who was then treated with intravenous streptokinase, would have a total score of (371171391511015181171[31215]) 5 148. This score corresponds to
predicted probability of 30% for cardiogenic shock occurring after thrombolytic therapy.
BP 5 blood pressure; MI 5 myocardial infarction; Tx 5 thrombolytic therapy; PTCA 5 percutaneous transluminal coronary angioplasty; CABG 5 coronary artery bypass
grafting surgery; tPA 5 tissue-plasminogen activator; SK 5 streptokinase; IV 5 intravenous; Combo 5 combination of tissue-plasminogen activator and streptokinase; SQ 5
subcutaneous; US 5 patients enrolled in the U.S.; Wght 5 weight.
with AMI without clinical signs of heart failure upon
presentation, cardiogenic shock developed in-hospital in 89
(2.6%) of 3,465 patients. Among the independent predic-
tors for in-hospital shock were older age, female sex, prior
angina, prior stroke and peripheral vascular disease. Hands
et al. (28) reported that shock developed in 60 (7.1%) of 845
patients admitted with AMI also in the prethrombolysis era.
Independent predictors of the occurrence of shock were age
.65 years, left ventricular ejection fraction ,35%, larger
infarct as estimated by serial enzyme determinations, prior
AMI and diabetes mellitus. In these earlier studies (27,28),
parameters from the physical examination were not included
in the analysis.
Our study of 1,889 patients who developed shock after
thrombolytic therapy complements these prior studies,
demonstrating again the strong association between in-
creased age and the occurrence of shock. Moreover, our
study underscores the importance of the physical examina-
tion; variables easily derived from the physical examination
were of much greater significance in predicting the occur-
rence of shock than other variables such as prior AMI or
infarct location. Similarly, we have recently demonstrated
that other variables derived from the physical examination
such as altered sensorium, oliguria and cold, clammy skin
were of great significance in predicting death among pa-
tients with shock (18).
Timing of shock. The challenge for the clinician is to
promptly and thoroughly identify the patient at risk for
developing shock and to avert this complication. In the
prethrombolysis era, Leor et al. (27) reported that shock
developed at a mean of 4 6 4 days after admission (median
two days, range 3 h to 16 days) in patients who were
admitted with Killip class I, and Hands et al. (28) reported
that shock occurred at a mean of 3.4 6 0.8 days (with half
the patients developing shock within the first 24 h) in
patients who did not have shock upon admission. More
recent data have stressed the earlier occurrence of shock
(7,12); shock occurred at a median of 9 h after onset of
AMI. In GUSTO-I, we observed that among patients who
did not present with shock and who received thrombolytic
therapy, shock developed at a median of 11.6 h. Moreover,
shock developed within 6 h in 39.6% of shock patients and
within 24 h in 63.2% of such patients. These data indicate
that the window of opportunity to attempt to avert the
development of shock is very short-lived; patients must be
identified and measures should be taken within hours of
presentation.
Study limitations. There are several caveats to consider in
interpreting our results. First, our analysis pertains only to
patients who did not die or develop shock before arrival at
the hospital and who were well enough to sign a written
informed consent to participate in a randomized trial.
Moreover, this cohort included only patients with ST-
segment elevation upon presentation who were eligible for
thrombolytic therapy. Second, some of the patients who
came in with a low blood pressure may have been in
subclinical shock. However, the study protocol also required
that the hypotension be accompanied by signs of hypoper-
fusion to define shock. Apparently the attending physicians
did not consider these patients to be in cardiogenic shock
using our definition.
Third, in the current study we identified patients at risk
of developing shock but did not prove that it is possible to
avert the occurrence of shock after thrombolytic therapy.
Although thrombolytic therapy in itself has reduced the
occurrence of shock (29,30), there is no evidence as yet that
other measures after thrombolytic therapy influence the
development of shock. However, revascularization after
thrombolytic therapy may be of value in high-risk popula-
tions, in contrast to its lack of effect when applied indis-
criminately (31,32). Unfortunately, in current clinical prac-
tice, revascularization is more commonly offered to lower-
risk patients (33–35).
In addition, the administration of therapeutic agents that
improve cardiac myocyte metabolism, such as IV glucose-
insulin-potassium solutions (36), may prove to be salutary.
Studies investigating the efficacy of aggressive revasculariza-
tion or other measures after thrombolytic therapy in pre-
venting shock in high-risk subpopulations, such as those
identified by our model, are warranted.
Conclusions. We devised a simple scoring system to pre-
dict the risk of cardiogenic shock occurring after thrombo-
lytic therapy, and we validated it in an independent cohort.
Based primarily on the age of the patient and findings easily
derived from the physical examination upon presentation, it
is possible to estimate with accuracy the risk of shock. The
physician attending to the patient with AMI now faces the
challenge of promptly identifying the patient at risk and
taking measures to avert the occurrence of shock.
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